Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on December 31, 2007 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Opioid-Related Disorders
Intervention: Methylphenidate (Drug)
Phase: Phase 1
Status: Active, not recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s): Frances R Levin, M.D., Principal Investigator, Affiliation: Research Foundation for Mental Hygiene, Inc.
Summary
The purpose of this study is to treat Adult Attention Deficit Hyperactivity Disorder (ADHD)
in methadone patients.
Clinical Details
Official title: Treatment of Adult ADHD in Methadone Patients
Study design: Treatment, Double-Blind
Primary outcome: Cocaine useADHD symptom severity Adverse effects
Detailed description:
This project is a three armed double-blind, placebo-controlled, randomized trial comparing
the efficacy of MPH and BPR, relative to each other and to placebo, for treating persistent
ADHD in methadone-maintained patients. One hundred and twenty subjects, will be randomized
to receive either MPH, BPR, or placebo with equal probability. Randomization will be
stratified by site, and whether or not cocaine is also being used. Efficacy will be
measured by treatment retention, reduction in illicit drug use and drug craving, improvement
of ADHD symptoms and overall functional status.
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Individuals who meet DSM-IV criteria for opiate dependence and are currently maintained on
methadone
Patients must meet DSM-IV criteria for persistent adult ADHD
Must be on stable methadone dose for at least 3 weeks
Individuals positive for HIV will not be excluded.
Exclusion Criteria:
Patients meeting DSM-IV criteria for current psychiatric disorders (other than ADHD or
substance abuse) which requires psychiatric intervention
Patients who are physiologically dependent on either sedatives or alcohol such that they
experience symptoms requiring medical attention during periods of abstinence or significant
reduction in amount of use
Individuals diagnosed with other forms of adult ADHD other than persistent, particularly
substance-induced ADHD
Those who have an unstable medical condition which might make participation hazardous,
including but not restricted to: uncontrolled hypertension, (SBP >160, DBP>100, PULSE
>110), uncontrolled liver disease, uncontrolled diabetes, acute hepatitis, uncontrolled
heart disease as indicated by history or abnormal ECG, glaucoma, or history of urinary
retention or seizures, or advanced AIDS will not be included
Patients who are taking prescription psychotropic medications other than methadone
Patients who have exhibited suicidal or homicidal behavior within the past two
years
Patients with known sensitivity to MPH or BPR
Patients with cognitive impairment or who cannot read or understand the self-report
assessment forms unaided or are so severely disabled they cannot comply with the
requirements of the study.
Patients unable to give full and informed consent
Patients with a history of an eating disorder
Patients recently convicted of a violent crime. (last two years)
Nursing mothers and pregnant women
Locations and Contacts
Research Foundation for Mental Hygiene, Inc., New York, New York 10032, United States
Additional Information
Substance and Research Service of the Division on Substance Abuse of the NYSPI
Starting date: February 1998
Last updated: November 3, 2005
|